Galera Therapeutics Inc
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treat… Read more
Galera Therapeutics Inc (GRTX) - Net Assets
Latest net assets as of December 2024: $-143.67 Million USD
Based on the latest financial reports, Galera Therapeutics Inc (GRTX) has net assets worth $-143.67 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.10 Million) and total liabilities ($153.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-143.67 Million |
| % of Total Assets | -1422.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2448.3% |
| 10-Year Change | N/A |
| Growth Volatility | 478.44 |
Galera Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Galera Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Galera Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Galera Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-143.67 Million | -9.52% |
| 2023-12-31 | $-131.19 Million | -20.15% |
| 2022-12-31 | $-109.18 Million | -88.23% |
| 2021-12-31 | $-58.00 Million | -1048.09% |
| 2020-12-31 | $6.12 Million | -91.21% |
| 2019-12-31 | $69.61 Million | +166.41% |
| 2018-12-31 | $-104.82 Million | -37.73% |
| 2017-12-31 | $-76.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galera Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38026100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $75.00K | % |
| Other Components | $312.62 Million | % |
| Total Equity | $-143.67 Million | 100.00% |
Galera Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Galera Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Westar Resources Ltd
AU:WSR
|
$1.25 Million |
|
Badlands Resources Inc
PINK:BDLNF
|
$1.25 Million |
|
Australasian Metals Ltd
AU:A8G
|
$1.25 Million |
|
LDB Capital Corp.
V:LDB-P
|
$1.25 Million |
|
NOVARTIS N (NOT.SG)
STU:NOT
|
$1.25 Million |
|
OSHKOSH (OK3.SG)
STU:OK3
|
$1.25 Million |
|
Jaya Swarasa Agung PT
JK:TAYS
|
$1.25 Million |
|
Nickelsearch Ltd
AU:NIS
|
$1.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galera Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -131,185,000 to -143,669,000, a change of -12,484,000.
- Net loss of 18,957,000 reduced equity.
- New share issuances of 2,223,000 increased equity.
- Other factors increased equity by 4,250,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.96 Million | -13.19% |
| Share Issuances | $2.22 Million | +1.55% |
| Other Changes | $4.25 Million | +2.96% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Galera Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-5.00 | $0.03 | x |
| 2018-12-31 | $-5.41 | $0.03 | x |
| 2019-12-31 | $2.81 | $0.03 | x |
| 2020-12-31 | $0.25 | $0.03 | x |
| 2021-12-31 | $-2.25 | $0.03 | x |
| 2022-12-31 | $-4.03 | $0.03 | x |
| 2023-12-31 | $-2.94 | $0.03 | x |
| 2024-12-31 | $-2.63 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galera Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-160.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.93 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.19 Million |
| 2019 | -74.60% | 0.00% | 0.00x | 1.77x | $-58.89 Million |
| 2020 | -1213.11% | 0.00% | 0.00x | 13.75x | $-74.83 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-81.93 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.30 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.96 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.59 Million |
Industry Comparison
This section compares Galera Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galera Therapeutics Inc (GRTX) | $-143.67 Million | 0.00% | N/A | $1.25 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |